Number with steroid resistance by one year · idiopathic steroid‐resistant nephrotic syndrome in children
Tacrolimus showed no clear difference in number with steroid resistance by one year compared with mycophenolate mofetil to maintain remission (low certainty).
1 finding from 1 review
Change in GFR · idiopathic steroid‐resistant nephrotic syndrome in children
1 finding from 1 review
Complete remission: all renal pathologies · idiopathic steroid‐resistant nephrotic syndrome in children
Oral cyclophosphamide showed no clear difference in complete remission: all renal pathologies compared with prednisone or placebo (low certainty).
1 finding from 1 review
Complete remission: FSGS · idiopathic steroid‐resistant nephrotic syndrome in children
Oral cyclophosphamide showed no clear difference in complete remission: FSGS compared with prednisone or placebo (low certainty).
1 finding from 1 review
Complete or partial remission · idiopathic steroid‐resistant nephrotic syndrome in children
Oral cyclophosphamide showed no clear difference in complete or partial remission compared with prednisone or placebo (low certainty).
1 finding from 1 review
Complete or partial remission: FSGS · idiopathic steroid‐resistant nephrotic syndrome in children
Oral cyclophosphamide showed no clear difference in complete or partial remission: FSGS compared with prednisone or placebo (low certainty).
1 finding from 1 review
Treatment failure · idiopathic steroid‐resistant nephrotic syndrome in children
Oral cyclophosphamide showed no clear difference in treatment failure compared with prednisone or placebo (low certainty).
1 finding from 1 review
Complete or partial remission: FSGS · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin showed no clear difference in complete or partial remission: FSGS compared with placebo or no treatment (low certainty).
1 finding from 1 review
Adverse events: death (all causes) · idiopathic steroid‐resistant nephrotic syndrome in children
Oral cyclophosphamide showed no clear difference in adverse events: death (all causes) compared with prednisone or placebo (low certainty).
1 finding from 1 review
Adverse events: hypertension with seizures · idiopathic steroid‐resistant nephrotic syndrome in children
It is very uncertain whether oral cyclophosphamide changes adverse events: hypertension with seizures compared with prednisone or placebo (very low certainty).
1 finding from 1 review
Complete remission · idiopathic steroid‐resistant nephrotic syndrome in children
IV showed no clear difference in complete remission compared with oral cyclophosphamide (low certainty).
1 finding from 1 review
Partial remission ( · idiopathic steroid‐resistant nephrotic syndrome in children
IV showed no clear difference in partial remission compared with oral cyclophosphamide (low certainty).
1 finding from 1 review
Remission · idiopathic steroid‐resistant nephrotic syndrome in children
IV showed no clear difference in continuing remission at one year compared with oral cyclophosphamide (low certainty).
1 finding from 1 review
Adverse events: renal insufficiency · idiopathic steroid‐resistant nephrotic syndrome in children
IV showed no clear difference in adverse events: renal insufficiency compared with oral cyclophosphamide (low certainty).
1 finding from 1 review
Adverse effects ‐ Bacterial infection clinical assessment · idiopathic steroid‐resistant nephrotic syndrome in children
It is very uncertain whether IV changes adverse events: bacterial infection compared with oral cyclophosphamide (very low certainty).
1 finding from 1 review
Adverse events: Vomiting · idiopathic steroid‐resistant nephrotic syndrome in children
It is very uncertain whether IV changes adverse events: vomiting compared with oral cyclophosphamide (very low certainty).
1 finding from 1 review
Alopecia · idiopathic steroid‐resistant nephrotic syndrome in children
IV showed no clear difference in adverse events: alopecia compared with oral cyclophosphamide (low certainty).
1 finding from 1 review
Complete remission (no further aphthous episodes to 6 months) · idiopathic steroid‐resistant nephrotic syndrome in children
IV cyclophosphamide showed no clear difference in treatment response at 6 months: complete remission compared with oral cyclophosphamide plus IV dexamethasone (low certainty).
1 finding from 1 review
Adverse events: worsening of hypertension · idiopathic steroid‐resistant nephrotic syndrome in children
It is very uncertain whether cyclosporin changes adverse events: worsening of hypertension compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Treatment response at 6 months: partial remission · idiopathic steroid‐resistant nephrotic syndrome in children
IV cyclophosphamide showed no clear difference in treatment response at 6 months: partial remission compared with oral cyclophosphamide plus IV dexamethasone (low certainty).
1 finding from 1 review